Clinically, in patients with septic acute kidney injury requiring kidney replacement therapy, the 28-day survival and mean arterial pressure response were higher in the angiotensin II group compared with the placebo group, and the release rate from kidney replacement therapy was higher, suggesting that patients with septic AKI requiring kidney replacement therapy may preferentially benefit from angiotensin II [79]. The gene discussed is AGT; the disease is acute kidney injury.